[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. (TRDA) – Form 4 Insider Transaction

On 07/09/2025, funds affiliated with venture-capital firm 5AM Ventures, a 10% beneficial owner of Entrada, reported open-market sales of the company’s common stock:

• 5AM Ventures V, L.P. sold 20,065 shares at $7.502 per share (≈ $150 k) and now holds 3,163,066 shares directly.
• 5AM Opportunities I, L.P. sold 6,935 shares at the same price (≈ $52 k) and now holds 1,093,313 shares indirectly.

No derivative securities were involved, and there were no purchases disclosed. The reporting group—comprising 5AM Partners entities and managing members Dr. Scott M. Rocklage and Andrew J. Schwab—continues to own more than four million shares in aggregate but trimmed its position by roughly 27,000 shares in a single session.

The transactions represent a relatively small reduction of the group’s overall stake yet may signal routine portfolio rebalancing or liquidity management by a long-term holder.

Positive

• 5AM Ventures retains a sizeable 3.16 million-share direct stake and 1.09 million shares indirectly, indicating continued strategic commitment.

Negative

• Insider group sold 27,000 shares worth ≈$0.2 million, which may introduce mild negative sentiment toward TRDA shares.

Insights

Securities Analyst

TL;DR – Small insider sale; negligible impact on ownership structure.

The reported sales equate to ≈$202 k, a fraction of 5AM’s >4 million-share position. From a market-impact standpoint, the disposition is minor and does not meaningfully alter the venture fund’s strategic exposure to Entrada. No new information on corporate fundamentals or operational outlook is provided. I view the filing as neutral for valuation; it merely updates the float and signals some liquidity taking.

Portfolio Manager

TL;DR – Insider selling creates slight negative sentiment but is immaterial.

While insider sales often trigger concern, the scale here—<1 % of the holder’s stake—suggests routine cash management. 5AM Ventures remains a core shareholder, preserving potential alignment with public investors. The sale price of $7.502 lies near recent trading levels, so no actionable price signal emerges. I assign a modestly negative bias due to the “sell” nature, but I would not alter a portfolio position based solely on this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

5AM Ventures V, L.P.

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2025		S		20,065	D	$7.502	3,163,066	D(1)
Common Stock	07/09/2025		S		6,935	D	$7.502	1,093,313	I	By 5AM Opportunities I, L.P.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

5AM Ventures V, L.P.

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

5AM Partners V, LLC

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

5AM Opportunities I, L.P.

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

5AM Opportunities I (GP), LLC

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ROCKLAGE SCOTT M

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Schwab Andrew J.

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

2. Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.

	5AM Ventures V, L.P., By: 5AM Partners V, LLC, its General Partner, By /s/ Scott M. Rocklage, Managing Member	07/11/2025
	5AM Partners V, LLC, By /s/ Scott M. Rocklage, Managing Member	07/11/2025
	5AM Opportunities I, L.P., By: 5AM Opportunities I (GP),LLC, its General Partner, By /s/ Kush Parmar, Managing Member	07/11/2025
	5AM Opportunities I (GP), LLC, By /s/ Kush Parmar, Managing Member	07/11/2025
	/s/ Scott M. Rocklage	07/11/2025
	/s/ Andrew J. Schwab	07/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who sold shares of Entrada Therapeutics (TRDA) on 07/09/2025?

The sellers were 5AM Ventures V, L.P. and 5AM Opportunities I, L.P., both 10% owners affiliated with 5AM Ventures.

How many TRDA shares were sold in the Form 4 filing?

27,000 shares in total—20,065 by 5AM Ventures V and 6,935 by 5AM Opportunities I.

At what price were the TRDA shares sold?

All shares were sold at $7.502 per share.

What is 5AM Ventures’ remaining ownership in Entrada Therapeutics?

After the sale, 5AM Ventures V directly holds 3,163,066 shares; 5AM Opportunities I indirectly holds 1,093,313 shares.

Did the Form 4 include any derivative security transactions?

No. The filing reported only common-stock sales; Table II for derivatives had no entries.